Spotlight
Topics
DI Executive
Subscribe
- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
FDA Clears Adjunctive Lung Ventilation Software for CT
With algorithms utilized in aerospace technology, the CT LVAS software reportedly provides enhanced assessment of regional airflow and lung ventilation.
The Food and Drug Administration (FDA) has granted 510(k) clearance for CT LVAS, an adjunctive software that provides detailed analysis of lung ventilation based on computed tomography (CT) scans.
Offering color-coded images of regional airflow and lung ventilation that are overlayed on CT scans, the CT LVAS provides quantifiable assessments of lung volume change and regional lung ventilation heterogeneity, according to 4DMedical, the developer of CT LVAS.
The company said the CT LVAS facilitates regional lung ventilation measurement in thousands of locations in the lungs.
“Having assisted with image interpretation of CT LVAS exams in Australia, I've seen the diagnostic power of adding functional assessment to the structural information provided in standard non-contrast chest CTs,” noted Greg Mogel, M.D., a consultant radiologist at 4DMedical. “CT LVAS allows radiologists to provide a whole new dimension of lung health information to referring clinicians needing answers.”
4DMedical added that the combination of CT LVAS with a forthcoming CT:VQ software, which provides quantitative perfusion assessment based on CT scans, may enhance the diagnosis of pulmonary embolism and assessment of conditions such as chronic obstructive pulmonary disease (COPD).
Recent Videos
Related Content
Can Radiomics Bolster Low-Dose CT Prognostic Assessment for High-Risk Lung Adenocarcinoma?
December 16th 2024Article
A CT-based radiomic model offered over 10 percent higher specificity and positive predictive value for high-risk lung adenocarcinoma in comparison to a radiographic model, according to external validation testing in a recent study.
Study Shows Merits of CTA-Derived Quantitative Flow Ratio in Predicting MACE
December 11th 2024Article
For patients with suspected or known coronary artery disease (CAD) without percutaneous coronary intervention (PCI), researchers found that those with a normal CTA-derived quantitative flow ratio (CT-QFR) had a 22 percent higher MACE-free survival rate.
The Reading Room: Racial and Ethnic Minorities, Cancer Screenings, and COVID-19
November 3rd 2020Podcast
In this podcast episode, Dr. Shalom Kalnicki, from Montefiore and Albert Einstein College of Medicine, discusses the disparities minority patients face with cancer screenings and what can be done to increase access during the pandemic.
